Literature DB >> 17384651

Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness.

Shahrokh F Shariat1, Alexandre R Zlotta, Raheela Ashfaq, Arthur I Sagalowsky, Yair Lotan.   

Abstract

The aim of this study was to evaluate the association between p53, p21, p27 and Rb expression, alone or in combination, with pathological features and clinical outcomes of urothelial carcinoma of the bladder. Immunohistochemical staining for p53, p21, p27 and pRB was performed on tissue microarrays comprising normal urothelium from nine controls, transurethral resection specimens from 74 patients with Ta, Tis and/or T1 bladder urothelial carcinoma, radical cystectomy specimens from 226 consecutive urothelial carcinoma patients, and lymph nodes with tumor invasion from 50 of the 226 cystectomy patients. All nine controls had normal status of biomarkers. The proportion of biomarkers alterations was highest in lymph node metastases. p53, pRB and p27 were associated with pathologic stage, lymphovascular invasion and lymph node metastases (P-values<or=0.050). Each biomarker alone, each combination of two biomarkers and the number of altered biomarkers were all independently associated with disease recurrence and bladder cancer-specific death (P-values<or=0.046). In patients with organ-confined disease, p53, p21 and p27 were independently associated with disease recurrence and bladder cancer-specific death (P-values<or=0.046). There was a good but not perfect concordance in the expression of biomarkers between matched transurethral resection and cystectomy specimens (n=22; concordance rates: 77-86%) and between matched lymph node and cystectomy specimens (n=50, 70-92%). In conclusion, p53, p21, p27 and pRB have a cooperative/synergistic role in the biologic behavior of bladder urothelial carcinoma. In contrast to the use of single biological markers, evaluation of their combined status may improve prognostic models and help identify patients who might benefit from adjuvant therapies and in decision-making.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17384651     DOI: 10.1038/modpathol.3800757

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  32 in total

Review 1.  Biomolecular predictors of urothelial cancer behavior and treatment outcomes.

Authors:  Michael Rink; Eugene K Cha; David Green; Jens Hansen; Brian D Robinson; Yair Lotan; Arthur I Sagalowsky; Felix K Chun; Pierre I Karakiewicz; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

2.  AMPKα2 Regulates Bladder Cancer Growth through SKP2-Mediated Degradation of p27.

Authors:  Stavros Kopsiaftis; Katie L Sullivan; Isha Garg; John A Taylor; Kevin P Claffey
Journal:  Mol Cancer Res       Date:  2016-09-16       Impact factor: 5.852

3.  Use of nomograms for predictions of outcome in patients with advanced bladder cancer.

Authors:  Shahrokh F Shariat; Pierre I Karakiewicz; Guilherme Godoy; Seth P Lerner
Journal:  Ther Adv Urol       Date:  2009-04

4.  Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder.

Authors:  Oliver Patschan; Shahrokh F Shariat; Daher C Chade; Pierre I Karakiewicz; Raheela Ashfaq; Yair Lotan; Kristina Hotakainen; Ulf-Håkan Stenman; Anders Bjartell
Journal:  World J Urol       Date:  2011-07-08       Impact factor: 4.226

Review 5.  Molecular substratification of bladder cancer: moving towards individualized patient management.

Authors:  Anirban P Mitra
Journal:  Ther Adv Urol       Date:  2016-03-28

6.  C5a receptor expression is associated with poor prognosis in urothelial cell carcinoma patients treated with radical cystectomy or nephroureterectomy.

Authors:  Yoshihiro Wada; Yoshihiro Maeda; Tatsuko Kubo; Ken Kikuchi; Masatoshi Eto; Takahisa Imamura
Journal:  Oncol Lett       Date:  2016-09-15       Impact factor: 2.967

7.  Time-dependent biological differences in molecular markers of high-grade urothelial cancer over 7 decades (ras proteins, pTEN, uPAR, PAI-1 and MMP-9).

Authors:  Jorunn Litlekalsoy; Jens G Hostmark; Daniela Elena Costea; Martin Illemann; Ole Didrik Laerum
Journal:  Virchows Arch       Date:  2012-10-06       Impact factor: 4.064

8.  The management of BCG failure in non-muscle-invasive bladder cancer: an update.

Authors:  Alexandre R Zlotta; Neil E Fleshner; Michael A Jewett
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

Review 9.  Prognostic value of cell-cycle regulation biomarkers in bladder cancer.

Authors:  Anirban P Mitra; Donna E Hansel; Richard J Cote
Journal:  Semin Oncol       Date:  2012-10       Impact factor: 4.929

Review 10.  p53 and chemosensitivity in bladder cancer.

Authors:  Hiroyuki Nishiyama; Jun Watanabe; Osamu Ogawa
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.